GLP-1 LIFE!

243 posts

GLP-1 LIFE! banner
GLP-1 LIFE!

GLP-1 LIFE!

@GLP1_LIFE

GLP-1 LIFE! is your daily dose of motivation, science, and real-world wins powered by the transformative potential of GLP-1 medications.

Fuquay-Varina, North Carolina Katılım Mart 2026
26 Takip Edilen2 Takipçiler
GLP-1 LIFE!
GLP-1 LIFE!@GLP1_LIFE·
@OUTTA_FOCUS The war is a long one. Getting the weight off is just one battle. How did they lose the war? The weight being gone adds many benefits to their health. Loose skin is the least of their problems.
English
0
0
0
2
GLP-1 LIFE!
GLP-1 LIFE!@GLP1_LIFE·
@EliLillyandCo You will be helping more people get better by delivering new medicines when you make these amazing medications accessible to the majority of people who need them.
English
0
0
0
43
GLP-1 LIFE! retweetledi
Eli Lilly and Company
Eli Lilly and Company@EliLillyandCo·
We’re helping more people get better by delivering new medicines, advancing the breakthroughs of tomorrow and bolstering R&D beyond our own labs. More on our Q1 results - e.lilly/4t6rh4w
Eli Lilly and Company tweet media
English
13
9
53
48.1K
U.S. FDA
U.S. FDA@US_FDA·
FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list. After careful review, we did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances. Public comment period now open. Learn more: fda.gov/news-events/pr…
English
53
39
151
97.9K
GLP-1 LIFE! retweetledi
On The Pen™
On The Pen™@ManOnThePen·
This would put the burden of meeting compounded GLP-1 demand on 503A pharmacies, who are not permitted to compound in bulk. I expect we will also see FDA action against those who do. So where does that demand go? Mostly to the unregulated grey market. Great. Super. All the docs so vocal in their opposition to regulated compounds get what they want. But let’s say for sake of argument these all go into shortage again because everyone switches to branded… We would certainly see shortages in branded happen again, especially with Medicare coming online in July. This would require B pharmacies to fire back up to help meet demand. In a world where Lilly has said REPEATEDLY that compounds aren’t eroding their branded sales, why not avoid all of this nonsense and just add them to the bulk substance list and ensure that most of the compound market is coming from GMP operations? $LLY $NVO
U.S. FDA@US_FDA

FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list. After careful review, we did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances. Public comment period now open. Learn more: fda.gov/news-events/pr…

English
15
9
76
18.2K
On The Pen™
On The Pen™@ManOnThePen·
🚨 BREAKING: The FDA just proposed keeping semaglutide, tirzepatide, and liraglutide OFF the 503B compounding list, stating there is no “clinical need” to compound them even when patients cannot afford or access branded versions. This is a major shift because if these drugs are not on the shortage list and not on the bulks list, the legal pathway for large scale compounding begins to disappear, which directly threatens access for millions relying on compounded GLP-1s. $LLY $NVO $HIMS
English
49
28
307
113.8K
GLP-1 LIFE! retweetledi
Peptide Critic
Peptide Critic@PeptideCritic·
Which peptide vendors actually deliver what they claim? Peptide Critic independently tracks lab test results, purity data, and pricing from 50+ vendors — so researchers can make informed decisions. Updated reviews now live. For research purposes only.
English
0
78
731
2.4M
GLP-1 LIFE! retweetledi
Tyler Black, MD
Tyler Black, MD@tylerblack32·
The discourse on GLP-1 is unhinged. Science brought a drug that : ⏬cardiovascular events reverses fatty liver ⏬kidney decline ⏬addictive cravings ⏬all-cause mortality And the worst, loudest part of the internet decides the real problem is that people are using it. /1
Tyler Black, MD tweet media
English
33
58
383
33K